A New Nasdaq Arrival With More Than a New Name
Biotechnology companies often arrive on Wall Street with an ambitious presentation and a conspicuously modest bank account. Mentari Therapeutics (Nasdaq: MTRI) has chosen a more substantial entrance. The Waltham, Massachusetts-based migraine-drug developer…
New Patient Research Strengthens the Case for MODD's Pivot
Medical technology often competes by adding features. Modular Medical (NASDAQ:MODD) is pursuing a different proposition: make insulin delivery less demanding for the people who must manage it every day. New patient research announced…
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
Higher Guidance Puts a Digital Health Turnaround in Focus
Amwell (NYSE: AMWL) is giving many a more compelling reason to revisit its digital healthcare story: a clearer route toward operating cash generation, a higher revenue outlook and a platform strategy built around…
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
Smaller Losses, Substantial Cash and a More Interesting Business
Amwell (NYSE: AMWL) heads into its third-quarter earnings announcement with a proposition worth watching: a technology-enabled healthcare business approaching adjusted operating breakeven, supported by nearly $196 million in cash and equivalents and a…
Healthcare’s most compelling growth stories often begin with an unglamorous proposition: make an existing problem less difficult to manage. For INOVIO Pharmaceuticals (NASDAQ: INO), that means a newly approved immunotherapy intended to reduce repeated surgeries. For IDEXX Laboratories (NASDAQ: IDXX), it means…
Michael J. Fox’s promotion to Companion of the Order of Canada on October 2, 2026, recognized a remarkable transformation: a celebrated actor had become one of the world’s most consequential advocates for Parkinson’s research. His foundation, established in 2000, has funded approximately…
AlloSure Kidney Data Excites, Dupixent Sales Surge and POTENTIAL Competitor, EP-104GI, Nears December EoE Catalyst
Biotechnology’s most persuasive growth stories are moving beyond laboratory promise and into financial statements, clinical evidence and approaching trial milestones. CareDx (NASDAQ: CDNA) reported third-quarter revenue growth…
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
